



United States Patent [19]

[11] **Patent Number:** **6,087,362**

El-Rashidy

[45] **Date of Patent:** **Jul. 11, 2000**

- [54] **APOMORPHINE AND SILDENAFIL COMPOSITION**
- [75] Inventor: **Ragab El-Rashidy**, Deerfield, Ill.
- [73] Assignee: **Pentech Pharmaceuticals, Inc.**, Buffalo Grove, Ill.
- [21] Appl. No.: **09/270,035**
- [22] Filed: **Mar. 16, 1999**
- [51] **Int. Cl.⁷** **A61K 31/495**; A61K 31/44
- [52] **U.S. Cl.** **514/253**; 514/284
- [58] **Field of Search** 514/284, 253

Wilson E., "Impotence Drugs: More than Viagra," *C&EN*, pp. 29-33 (Jun. 29, 1998).

Japsen B., "Impotency drug trials promising for Abbott," *Chicago Tribuen*, Business Section, pp. 1-2 (Sep. 4, 1998).

Kaplan S. et al., "Combination Therapy Using Oral Alpha-Blockers and Intracavernosal Injection in Men With Erectile Dysfunction," *Urology* 52(5), pp. 739-743 (1998).

Utiger R., "A Pill for Impotence," *The New England Journal of Medicine*, 338(20), pp. 1458-1459 (May 14, 1998).

VIAGRA™, Prescription Information published by PRO-MARK® Pharmacies, <http://www.pro-mark-pharmacies.com/viagra.html> (May 8, 1998).

[56] **References Cited**

U.S. PATENT DOCUMENTS

5,256,652	10/1993	El-Rashidy	514/58
5,770,606	6/1998	El-Rashidy et al.	514/284

OTHER PUBLICATIONS

Leland, J., "A Pill for Impotence?," *Newsweek*, pp. 62-68, (Nov. 17, 1997).

Goldstein et al., "Oral Sildenafil in the Treatment of Erectile Dysfunction", *The New England Journal of Medicine*, 338(20), pp. 1397-1404 (1998).

Handy B., "The Viagra™ Craze," *Time*, pp. 50-57 (May 4, 1998).

Valdes-Rodriguez A., "Viagra for her," *Chicago Tribune*, Womanews Section 13, p. 7 (Dec. 20, 1998).

Primary Examiner—Raymond Henley, III
Attorney, Agent, or Firm—Olson & Hierl, Ltd.

[57] **ABSTRACT**

The treatment of sexual dysfunction in human patients by an oral therapy regimen of administration of apomorphine and sildenafil is disclosed. This treatment optimizes the efficacy of each drug and substantially minimizes the undesirable side effects associated individually therewith. Apomorphine and sildenafil can be co-administered with a combination dosage unit or administered sequentially in separate dosage units, substantially prior to sexual activity. Other erectogenic agents can be administered along with apomorphine and sildenafil.

20 Claims, No Drawings

APOMORPHINE AND SILDENAFIL COMPOSITION

FIELD OF THE INVENTION

This invention relates to compositions, dosage forms and methods for treating sexual dysfunction in humans. More particularly, this invention relates to the use of compositions containing apomorphine and sildenafil.

BACKGROUND OF THE INVENTION

A normal erection occurs as a result of a coordinated vascular event in the penis. This is usually triggered neurally and consists of vasodilation and smooth muscle relaxation in the penis and its supplying arterial vessels. Arterial inflow causes enlargement of the substance of the corpora cavernosa. Venous outflow is trapped by this enlargement, permitting sustained high blood pressures in the penis sufficient to cause and maintain rigidity. Muscles in the perineum also assist in creating and maintaining penile rigidity. Erections are induced centrally in the nervous system by sexual thoughts, fantasy, and/or stimulation and can be reinforced locally by reflex mechanisms (e.g., tactile stimulation).

Impotence or male erectile dysfunction is defined as an inability to achieve and sustain an erection sufficient for satisfactory sexual performance and intercourse. Impotence in any given case can result from psychological disturbances (psychogenic), from physiological abnormalities in general (organic), from neurological disturbances (neurogenic), hormonal deficiencies (endocrine) or from a combination of the foregoing.

As used herein, psychogenic impotence is defined as functional impotence with no apparent overwhelming organic basis. It may be characterized by an ability to have an erection in response to some stimuli (e.g., masturbation, spontaneous nocturnal, spontaneous early morning, video erotica, etc.) but not others (e.g., partner or spousal attention).

Current diagnosis of and professional thinking on the etiology of male erectile dysfunction has focused on the severity of the condition, i.e., mild, moderate and severe. One method of diagnosis employs oral medication as a means to distinguish dysfunctional patients who can respond to oral medications from those who require more direct intervention, i.e., such as intracavernosal injection or surgery.

Oral medicines, are particularly desirable and sought after discreet forms of treatment. See, for example, Leland J., "A Pill for Impotence?," *Newsweek*, pp. 62-68 (Nov. 17, 1997).

Apomorphine, a selective dopamine receptor agonist, has been widely utilized as an emetic agent, sedative, antiparkinsonian agent and a behavior altering agent and previously was shown to have very poor oral bioavailability. See, for example, Baldessarini et al., in Gessa et al., eds., *Apomorphine and Other Dopaminomimetics, Basic Pharmacology*, 1, pp. 219-228, Raven Press, N.Y. (1981). However, recent research and clinical studies of the effect of orally administered apomorphine on penile tumescence in male patients afflicted with psychogenic impotence show that oral administration of apomorphine can indeed induce an erection in a psychogenic male patient in response to physical sexual stimulation. The specific mechanisms by which apomorphine acts to produce an erectile response in a human male are not yet completely understood, but are believed to be centrally acting through dopamine receptor stimulation in the medial preoptic area of the brain.

While apomorphine can be orally administered in an effective dose, the dose required to achieve a significant erectile response must not be accompanied by substantial nausea and vomiting, or other undesirable side effects, such as arterial hypotension, flushing and diaphoresis (sweating). At dosages of more than 6 milligrams, for example, in some instances the level of accompanying nausea and vomiting interferes with the benefit in treating male erectile dysfunction with apomorphine.

During normal penile erections, when the inflow of blood to the corpora cavernosa engages the sinusoidal spaces, the trabecular tissue compresses small cavernosal veins against the thick fibrous tissue surrounding the corpora to maintain the erection. To mediate these changes in blood flow, nitric oxide is released from postsynaptic parasympathetic neurons and, to a lesser extent, endothelial cells and α -adrenergic neurons are inhibited in the arterial and trabecular smooth muscle. Nitric oxide, which is readily diffusible, stimulates the formation of increased cyclic guanosine monophosphate (GMP) in the corpus cavernosum by guanylate cyclase to relax the smooth muscle cells.

Recently, the oral use of the citrate salt of sildenafil has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of male erectile dysfunction. Sildenafil is reported to be a selective inhibitor of cyclic-GMP-specific phosphodiesterase type 5 (PDE5), the predominant isozyme metabolizing cyclic GMP formed in the corpus cavernosum. Since sildenafil is a potent inhibitor of PDE5 in the corpus cavernosum, it is believed to enhance the effect of nitric oxide, thereby increasing cavernosal blood flow in the penis, especially with sexual stimulation. Inasmuch as sildenafil at the currently recommended doses of 25-100 mg has little effect in the absence of sexual stimulation, sildenafil is believed to restore the natural erectile response to sexual stimulation but not cause erections in the absence of such stimulation. See, for example, Goldstein et al., "Oral Sildenafil in the Treatment of Erectile Dysfunction," *The New England Journal of Medicine*, 338, pp 1397-1404 (1998). The localized mechanism by which cyclic GMP stimulates relaxation of the smooth muscles has not been elucidated.

In dose-response studies, increasing doses of sildenafil (25 to 100 mg) reportedly increased the erectogenic efficacy of sildenafil. However, the oral administration of sildenafil is also accompanied by dose-responsive undesirable side effects. Consequently, at dosages higher than 50 milligrams, the incidence of such side effects as abnormal vision problems ranging from blue or green halo effects to blurring, dyspepsia, nasal congestion, blinding headaches, flushing redness, diarrhea, dizziness, rash, and urinary tract infection increases.

Other more serious side effects have been reported, such as syncope (loss of consciousness), priapism (erection lasting 4 hours or more) and increased cardiac risk (coital coronaries), can be brought on in some cases by physiological predisposition, adverse drug interaction or potentiation, or by drug abuse. In particular, hypotension crisis can result from the combination of sildenafil citrate and organic nitrates, causing, in some cases death, so its administration to patients who are concurrently using organic nitrates (such as nitroglycerin) in any form is contraindicated. Moreover, the long-term effects of large doses of sildenafil containing drugs is not known. See, for example, Handy B., "The Viagra™ Craze," *Time*, pp 50-57 (May 4, 1998).

Some attempts have been made to treat sexual dysfunction in females caused by hysterectomy, menopause and

vascular disorders, like diabetes, by employing topical gels containing Viagra™. See, for example, Valdes-Rodriguez, A, "Viagra for her," *Chicago Tribune*, Womanews Section 13, p 7 (Dec. 20, 1998).

Thus there is an ongoing need and desire for a discreet, convenient treatment of sexual dysfunction in humans, suitable for men or women, and preferably for oral delivery systems without the incidence or likelihood of undesirable attendant side effects.

SUMMARY OF THE INVENTION

The present invention provides a therapy regimen of oral administration of apomorphine and sildenafil compositions. Apomorphine and sildenafil can be either co-administered or administered sequentially, prior to sexual activity. A practical therapeutic delivery system is provided employing apomorphine and sildenafil which system sustains satisfaction during sexual activity; i.e., it optimizes the erectile penile response in human males and clitoral response in females to sexual stimuli while minimizing the undesirable side effects associated individually therewith. The oral compositions are preferably administered in sublingual dosage forms.

In one composition embodiment suitable for oral therapy, apomorphine and sildenafil can be concurrently co-administered as a combination sublingual dosage unit. Sublingual combination dosage units preferably contain apomorphine in the range of about 1 to about 6 milligrams (mg) and sildenafil in the range of about 10 to about 75 mg, so long as the final dosage combination received by the patient is accompanied by minimal or substantially no undesirable side effects. A preferred sublingual combination dosage unit contains about 2 mg apomorphine and about 15 to about 50 mg sildenafil.

For sequential administration therapy, apomorphine and sildenafil are administered in separate dosage units each of which employs a lesser dosage amount of the respective drug than is required for achieving the same level of erectile response when it is used as the sole active medicament. Composition embodiments suitable for sequential administration of sildenafil and apomorphine, preferably each in sublingual dosage form, preferably contain sildenafil in a range of about 10 to about 75 mg, more preferably in the range of about 15 to about 50 mg, and apomorphine in a range of about 1 to not more than 6 mg, more preferably in the range of about 2 to about 5 mg so long as the total dose combination received by the patient is accompanied by minimal or substantially no undesirable side effects.

The administration of apomorphine and sildenafil, either co-administered or administered sequentially, beneficially provides a discreet, convenient therapy regimen for effectively achieving and maintaining erections sufficient for vaginal penetration in response to physical sexual stimuli within a practical therapy period.

For co-administration of sildenafil and apomorphine, the combination dosage unit preferably is taken by a male patient suffering from erectile dysfunction about 20–45 minutes before sexual activity to achieve and maintain an erection of sufficient rigidity for vaginal penetration with substantially no attendant adverse side effects, most notably, substantially no nausea and vomiting.

For sequential administration, the male patient preferably takes one dosage unit of sildenafil containing the appropriate sildenafil dosage and one dosage unit of apomorphine containing the appropriate apomorphine dosage substantially within 30–60 minutes of one another and within 15–30 minutes prior to sexual activity.

It has now been found that an oral therapy regimen employing apomorphine and sildenafil in combination with one another can effectively optimize the initiation and maintenance of penile erection in response to sexual stimuli and minimize the side effects associated with each respective medicament. Moreover optimization is achieved at dosage levels below the efficacy levels required in oral therapies employing each drug as the sole medicament.


Further, apomorphine and sildenafil can also be combined, for concurrent or sequential administration therapies, with lesser amounts of erectogenic agents selected from adrenal steroids, such as testosterone, dehydroepiandrosterone (DHEA), and the like; alpha receptor blockers, such as phentolamine, yohimbine, prazosin, doxazosin, terazosin, trimazosin, and the like; or peripheral vasodilators, such as prostaglandin E₁ (alprostadil), and like smooth muscle relaxants. Preferably, the erectogenic agents are added in an amount in the range of about 50 to about 100 percent by weight of the weight of apomorphine administered.

Advantageously, practicing the method of this invention, avoids or minimizes the possibility of abusive use of sildenafil because the emetic effect of increased apomorphine ingestion makes the combination substantially self-limiting.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Apomorphine is a dopamine receptor agonist that has a recognized use as an emetic when administered subcutaneously in about a 5-milligram dose. For the purposes of the present invention, apomorphine or a similarly acting dopamine receptor agonist, is administered in an amount sufficient to excite cells in the mid-brain region of the patient but with minimal side effects. This cell excitation is believed to be part of a cascade of stimulation that is likely to include neurotransmission with serotonin and oxytocin and which initiates erection upon physical sexual stimulation.

The dopamine receptors in the mid-brain region of a patient can be stimulated to a degree sufficient to cause an erection by the sublingual administration of apomorphine. Apomorphine, also known by the chemical name (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo- [de,g] quinoline-10, 11-diol, has the following chemical structure:




Apomorphine exists in a free base form or as an acid addition salt. For the purposes of the present invention apomorphine hydrochloride is preferred; however, other pharmacologically acceptable moieties thereof can be utilized as well. The term "apomorphine" as used herein includes the free base form of this compound as well as the pharmacologically acceptable acid addition salts thereof. In addition to the hydrochloride salt, other acceptable acid addition salts are the hydrobromide, the hydroiodide, the bisulfate, the phosphate, the acid phosphate, the lactate, the citrate, the tartarate, the salicylate, the succinate, the maleate, the gluconate, and the like.

Sublingual administration of apomorphine preferably takes place over a time period in the range of about 2 to about 10 minutes, or longer. When apomorphine is the sole therapeutic agent, the amount of apomorphine administered sublingually over this time period preferably is in the range of about 5 to about 74 micrograms per kilogram ($\mu\text{g}/\text{kg}$) of the patient's body weight, and most preferably within the range of about 50 to about 74 $\mu\text{g}/\text{kg}$ of body weight.

A maximum plasma concentration (C_{max}) of the apomorphine drug at which the onset of adverse effects, such as nausea, occur in human male subjects is at a threshold C_{max} of about 2.5 nanograms/milliliter (ng/ml). Plasma concentration is preferably maintained at no more than 5.5 ng/ml during sexual activity, when apomorphine is the sole active agent.

Sildenafil is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl piperazine and has the following structural formula:



The term "sildenafil" as used herein includes the free base form of this compound as well as pharmacologically acceptable acid addition salts thereof formed with organo-carboxylic acids, organo-sulphonic acids or inorganic acids. For purposes of the present invention, the organo-carboxylic acid salt, sildenafil citrate, having a solubility in water of 3.5 mg/ml is particularly preferred. Reference to "sildenafil" includes sildenafil citrate.

Sildenafil citrate is presently the active ingredient of a commercial medication for impotence sold under the designation Viagra™ (Pfizer Labs, N.Y.) formulated in tablets equivalent to 25 mg, 50 mg and 100 mg sildenafil for oral administration. According to the manufacturer, in addition to the active ingredient, sildenafil citrate, each tablet contains the following inactive ingredients: microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, lactose, triacetin, and FD&C Blue #2 aluminum lake.

It is known from *in vitro* studies that sildenafil is approximately 4,000 fold more selective for inhibiting phosphodiesterase type 5 (PDE5) than on other known phosphodiesterases, such as PDE3, which is involved in control of cardiac contractility. Sildenafil is reportedly only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and it is this lower selectivity which is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels.

Sildenafil, administered as the commercially available Viagra™ formulation, is reported to be rapidly absorbed after oral administration, with absolute bioavailability of about 40%. Its pharmacokinetics are dose-proportional over

the recommended dose range. Based on the Viagra™ manufacturer's product literature, maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When the Viagra™ formulation is taken with a high fat meal, the rate of absorption is reduced, with a mean delay in T_{max} of 60 minutes and mean reduction in C_{max} of 29%. The mean steady state volume of distribution (V_{ss}) for sildenafil is reportedly 105 L, indicating distribution into the tissues. Based upon reported measurements of sildenafil in the semen of healthy volunteers 90 minutes after dosing, less than 0.001% of the administered dose appeared in the semen of the patients.

Ordinarily when higher doses of apomorphine alone are administered sublingually, apomorphine is administered preferably about 15 to about 20 minutes prior to sexual activity to affect that part of the brain that initiates erection and when higher doses of sildenafil alone are administered, sildenafil is taken about 1 hour or more before sexual stimulation to induces smooth muscle cell relaxation for maintaining an erection. Surprisingly, a therapeutically effective dosage combination of apomorphine and sildenafil employed with the compositions of this invention maximizes the beneficial erectogenic efficacy of both apomorphine and sildenafil at dosages of each drug substantially lower than required respectively and substantially minimizes nausea or undesirable side effects associated with such dosages.

Illustrative preferred sublingual dosage forms for co-administration of apomorphine are set forth in Table I, below.

Sublingual combination dosage units preferably contain apomorphine in the range of about 1 to not more than 6 milligrams (mg), preferably in the range of about 2 and about 5 mg and of sildenafil in the range of about 10 to about 75 mg, preferably in the range of about 15 to about 50 mg, so long as the combined dose received by the patient is accompanied by minimal or substantially no undesirable side effects. A particularly preferred sublingual combination dosage unit contains about 2 mg apomorphine and not more than 50 mg sildenafil, more preferably about 2 mg apomorphine and not more than about 25 mg sildenafil.


Alternatively, the apomorphine and sildenafil may be formulated separately in the foregoing compositions as the sole active ingredient for practicing sequential administration of each respective drug.

For sequential administration therapy, sildenafil and apomorphine each is administered in a separate dosage unit containing a lesser dosage amount of respective drug than is required for achieving the same level of erectile response when the drug is the sole medicament. For sequential administration of sildenafil, the dosage unit preferably contains sildenafil in a range of about 10 to about 75 mg, more preferably in the range of about 15 to about 50 mg, and for administration of apomorphine the dosage unit preferably contains apomorphine in a range of about 1 to not more than 6 mg, more preferably in the range of about 2 to about 5 mg so long as the total combined dose received by the patient is accompanied by minimal or substantially no undesirable side effects.

A particularly preferred sequential administration dosage unit of sildenafil contains sildenafil in the range of about 15 to about 35 mg and of apomorphine contains apomorphine in the range of about 2 to about 4 mg. Preferably, each drug is administered sublingually. Alternatively, each drug can be administered by different oral routes; i.e., one can be ingested and the other administered sublingually or by buccal patch.

Preferably, sublingual dosage forms dissolve within a time period of at least about 2 minutes but less than about 10 minutes. The dissolution time can be longer, however, if desired as long as the necessary plasma concentration of apomorphine and sildenafil can be maintained. More preferably, the dissolution time in water for the presently contemplated dosage forms is about 3 minutes to about 5 minutes.

If desired, to facilitate absorption and thus bioavailability, absorption enhancing agents, such as cyclodextrins, particularly β -cyclodextrin, or a derivative thereof, such as hydroxypropyl- β -cyclodextrin (HPBCD) and the like may be included. Cyclodextrins are a group of cyclic, nonreducing oligosaccharides built up from six, seven or eight glucopyranose rings, respectively known as alpha, beta and gamma cyclodextrins. The cyclodextrins are a class of cavity-containing cyclic compounds possessing the property of forming a molecular inclusion complexes, which anchor or entrap another chemical compounds without the formation of covalent bonds. HPBCD is a cyclic polymer having a doughnut-shaped molecular structure including an inner cavity, as shown below:



Hydroxypropyl- β -cyclodextrins are commercially available compounds that are derived from β -cyclodextrins by condensation with a propylene oxide to provide the corresponding hydroxypropyl derivatives having a degree of substitution (D.S.) of up to about 15 or higher. For the purposes of the present invention a D.S. value of about 5 to 7 is preferred.

The preparation of such suitable hydroxypropyl- β -cyclodextrins is described, inter alia, in the *International Journal of Pharmaceutics*, 29, 73-82 (1986) and in the *Journal of Pharmaceutical Sciences*, 75 (6), 571-572 (1986). Also known and suitable for the present invention are the hydroxypropyl- β -cyclodextrins that are polyethers of cyclodextrins and are obtained by the condensation of an excess of hydroxypropylene oxide with β -cyclodextrin as described in U.S. Pat. No. 3,459,731. to Gramera et al. Hydroxypropyl- β -cyclodextrin (HPBCD) is particularly preferred cyclodextrin constituent, but is not limited thereto. The weight percent of the HPBCD in the composition is

preferably in the range of about 1 to about 10 weight percent of the total composition.

Particularly in the case of sildenafil, it has been found that HPBCD enhances bioavailability. Thus, the desired therapeutic effect can be achieved with a relatively lower dose of sildenafil, thereby minimizing the likelihood of adverse affects.

For effective sequential administration of sildenafil and apomorphine, the release of each drug is preferably staggered to maximize the beneficial inducement of erection by apomorphine and maintenance of erection by sildenafil upon sexual stimulation.

To augment the beneficial effect of apomorphine and sildenafil therapy, lesser amounts of erectogenic agents can be included. The term "erectogenic agents" as used herein refers to adrenal steroids, such as testosterone, dehydroepiandrosterone (DHEA) and the like; alpha receptor blockers, such as phentolamine, yohimbine, prazosin, doxazosin, terazosin, trimazosin and the like; or peripheral vasodilators, such as prostaglandin E₁ (alprostadil) and like smooth muscle relaxants that are known to improve the blood flow in the vascular system. Preferably, the erectogenic agents are

added in an amount in the range of about 50 to about 100 percent by weight, more preferably in the range of about 60 to about 80 percent by weight of the weight of apomorphine administered.

While nausea from the use of the inventive combination of apomorphine and sildenafil is unlikely, the onset of nausea, should it occur, can also be substantially obviated or delayed by including an antiemetic agent. Antiemetic agents are antinauseant drugs that prevent or substantially reduce nausea and vomiting. As used herein, the terms "antiemetic agent" and "antinausea agent" are interchangeable and mean a pharmaceutically acceptable compound that substantially reduces nausea symptoms.

Antiemetic agents that can be used in conjunction with apomorphine in the present compositions are antidopaminergic agents, such as the benzamides, e.g., metoclopramide, trimethobenzamide, benzquinamid, and the like; the phenothiazines, e.g., chlorpromazine, prochlorperazine, pipamazine, thiethylperazine, oxypendyl hydrochloride,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.